Uro-Vaxom

Pharmacological properties

uro-vaccine is an immunostimulating agent that has the following effect: it stimulates t-lymphocytes, induces the production of endogenous interferon and increases the amount of immunoglobulin a (iga), including in the urine.

Pharmacokinetics No data available.

Indications

Prevention of relapse of chronic lower urinary tract infections. combined treatment of acute urinary tract infections.

Application

Prevention: 1 capsule daily, in the morning on an empty stomach for 3 months.

Treatment in acute conditions: 1 capsule daily, in the morning on an empty stomach, as an additional treatment during antimicrobial therapy until symptoms disappear, but not less than 10 days.

If it is difficult for a child to swallow a capsule, open it and mix the contents with liquid (fruit juice, water).

Contraindications

Hypersensitivity to the components of the drug.

Side effects

The following adverse reactions are classified by organ systems and frequency of occurrence in accordance with the data of clinical studies and / or use in the post-registration period.

Often: 1/10 - ≥1 / 100; infrequently: 1/100 - ≥1 / 1000; rarely: 1/1000 - ≥1 / 10,000; very rare: 1/10 000, including isolated cases.

From the immune system. Infrequently: hypersensitivity reactions. Very rare: swelling of the oral cavity.

From the nervous system. Often: headache.

From the digestive system. Often: nausea, diarrhea, stomach discomfort, dyspepsia. Infrequently: abdominal pain.

On the part of the skin and subcutaneous tissue. Infrequently: rash, itching. Very rare: alopecia.

General disorders and changes in the injection site. Infrequently: fever. Very rare: peripheral edema.

special instructions

When using the drug with uro-vaccine, hypersensitivity reactions may occur, such as skin reactions, fever or swelling. in the event of such reactions, the use of the drug should be discontinued, as this may be a manifestation of allergic reactions.

Immunosuppressants can weaken or completely suppress the effect of the drug Uro-Vaxom.

Use during pregnancy and lactation.

Pregnancy. The amount of data on the use of the drug Uro-Vax in pregnant women is small. One pilot study was conducted with a small group (n = 62) of pregnant women with acute urinary tract infections, starting from the second trimester of pregnancy and before childbirth. Studies of the use of the drug in pregnant women in the first trimester of pregnancy have not been conducted. When using the drug Uro-Vax during pregnancy, especially in the first trimester, the benefits of using the drug for the pregnant woman and the potential risk to the fetus should be assessed.

Breastfeeding. There is no data on the use of the drug during lactation. When using the drug Uro-Vax during breastfeeding, the benefits of using the drug for the mother and the potential risk for the baby should be assessed.

Children. The drug is prescribed for children aged 4 years.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. No studies. It is unlikely that the drug affects the reaction rate when driving vehicles or other mechanisms.

Interactions

Until now, there is no data on the interaction of uro-vaccines with other drugs.

Overdose

Cases of overdose are not registered.

Storage conditions

At a temperature not exceeding 25 ° C.

ALL / 2017/0003 / UA / Dec / 2017 / Morion / 15000